Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Defends Its Offensive Strategy For Keytruda

Executive Summary

Merck reports $314m for PD-1 inhibitor Keytruda in second quarter, mostly from melanoma indication, leaving it far behind Bristol's Opdivo. Pressed about its competitive strategy, company execs touted first-to-market advantage in first-line lung cancer and a "wall of data" that will protect in the future.

Advertisement

Related Content

Under Fire, Bristol Plans To Pick Up The IO Pieces
Opdivo's Failure In First-Line Lung Cancer Prompts Rethink On Trial Endpoints
Does CheckMate 026 Take Bristol Out Of The End Game?
Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer
Gilead's Epclusa And Merck's Zepatier Hep C Combos Get EMA backing
Sales Down, Discounts Up: Hepatitis C Market Feeling Zepatier Launch
Merck Is Finding PD-L1 Testing Is Helping Keytruda
Medicaid May Offer Best Opportunity For Merck’s Zepatier

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097023

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel